{"meshTags":["Animals","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Pyridazines","Imidazoles","Antineoplastic Combined Chemotherapy Protocols","Drug Resistance, Neoplasm","Humans","Pyridines","Anilides"],"meshMinor":["Animals","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Pyridazines","Imidazoles","Antineoplastic Combined Chemotherapy Protocols","Drug Resistance, Neoplasm","Humans","Pyridines","Anilides"],"genes":["BCR","ABL","BCR","ABL"],"publicationTypes":["Comment","Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.","title":"Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies.","pubmedId":"23382113"}